Navigation Links
TorkLaw Responds to FDA Warning Letter to St. Jude Medical Regarding Defective Heart Device; Now Representing Patients in 15 States
Date:2/8/2013

LOS ANGELES, Feb. 9, 2013 /PRNewswire/ -- Product liability law firm TorkLaw continues to pursue litigation against St. Jude Medical on behalf of injured patients and their families.

In December 2011, the Food and Drug Administration issued a Class 1 recall for the St. Jude Medical Riata leads after many adverse events were being reported in patients. Studies showed that the leads which connect the heart defibrillator to the heart were failing due to insulation problems referred to as externalization.  A Class 1 Recall is the highest level recall that exists because the product poses a reasonable probability of serious adverse health consequences or death.

TorkLaw is now representing patients in fifteen states who have been affected by the recalled Riata leads and continues its ongoing investigation.  "We are speaking with patients from all over the country who have suffered from life-threatening injuries as a result of the defects found in St. Jude Medicals's heart devices," said Reza Torkzadeh , Senior Partner at TorkLaw.

The wires in the St. Jude Riata leads were found to protrude or perforate through the insulation resulting in lead failure, errant shocks, migration and other injuries.  Removal of leads is a very complex and potentially dangerous operation.   

"We are seeing a wide range of injuries caused by the defective leads.  All of these individuals have suffered a level of anxiety and pain that most of us will never understand," said Torkzadeh, who says his firm is committed to seeing that St. Jude is held accountable. 

The latest FDA investigation into St. Jude Medical was focused on the newer Durata leads also manufactured by St. Jude. In an official FDA warning letter to St. Jude Medical, dated January 10, 2013, the government agency cites St. Jude Medical for multiple manufacturing and quality control problems at their facility in Sylmar, California.

"The latest warning letter from the FDA raises a lot of red flags.  The FDA makes it very clear that their month-long inspection resulted in pinpointing the systematic failure of St. Jude Medical to follow approved manufacturing processes, proper monitoring, analysis, quality control and testing. That is not acceptable," said Torkzadeh.

TorkLaw is providing free legal consultations to those who have been affected by the St. Jude Medical heart defibrillator and Riata Leads.  Call today for a free consultation 888.222.8286.


'/>"/>
SOURCE The Torkzadeh Law Firm
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TorkLaw Accepting DePuy Hip Implant Cases
2. TorkLaw Accepting St. Jude Medical Device Cases
3. Medbox Responds to Unprecedented Rise in Stock Price
4. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
5. Concord Medical Responds to Unusual Market Activity in its Stock
6. iMD Companies responds to shareholder questions
7. Icahn Responds To Forest Labs Board
8. Physician-Patient Alliance for Health & Safety: Addressing The Joint Commission Opioid Warnings Can Reduce Respiratory Depression and Improve Patient Safety in Hospitals
9. First Warning Systems Receives Investment by Members of the Reno Angels and Local Investors
10. National Sleep Expert Issues Warning about Popping Pills to Replace Sleep
11. Lifeline Biotechnologies First Warning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 17, 2017   Tocagen Inc ., a clinical-stage, cancer-selective gene ... vice president, research and pharmaceutical development at Tocagen, will present at ... held Jan. 17-20 in Miami . ... ... manufacturing for replicating viruses - what to do when and why ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, ... Forecast to 2021" report to their offering. ... The global active pharmaceutical ingredients ... USD 157.95 Billion in 2016, growing at a CAGR of 6.3% ...
(Date:1/17/2017)... , Jan. 17, 2017 Immune Pharmaceuticals (NASDAQ: ... company, announced today that it will hold a Satellite Symposium ... Acute Leukemias (ISAL) XVI in Munich, Germany ... "Reinforcing the Efficacy of Immunotherapy for the maintenance of ... on Monday February 20 th , 2017 from 12:45 – ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, ... highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, ... this elite group of providers. , Produced by Zeltiq, CoolSculpting is approved by ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... will lecture to primary eye care practitioners on the latest breakthroughs in the ... 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New ... the region, is launching a charity drive to raise awareness of heart disease and ... killer in America, and is responsible for 1 in every 4 deaths at the ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
(Date:1/17/2017)... Tyler, TX (PRWEB) , ... January 17, 2017 ... ... serving Texas families from two offices in Tyler, has announced the latest beneficiary ... Red Ribbon Wish Network, a nonprofit organization dedicated to fulfilling the dreams of ...
Breaking Medicine News(10 mins):